Trial Profile
A Single Centre Study Investigating the Safety and Efficacy of an Immune Modulation Regimen in Mitigating the Alloimmune Response to Intravenous Laronidase in Infants With Severe Mucopolysaccharidosis type I (Hurler syndrome) Prior to Haematopoietic Stem Cell Transplantation
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Laronidase (Primary) ; Methotrexate
- Indications Mucopolysaccharidosis I
- Focus Therapeutic Use
- 18 Mar 2016 Status changed from not yet recruiting to recruiting as reported by United Kingdom Clinical Research Network.
- 10 Nov 2015 New trial record